IP Library Granted Patent US 7,241,571
Granted Patent B2
US 7,241,571 · App. 10/741,292 · Granted Jul 10, 2007

Identification of 5-lipoxygenase as a major gene contributing to atherosclerosis

Assignee: The Regents of the University of California
View Patent ↗
Loading inventors, assignments & file history…
Monitor This Case
Get email alerts when status or documents change.
Order Certified Copies
Most orders are placed with the USPTO same day — all within 24 business hours.
Order via The Patent Place →
Pre-filled with this patent's details
Quick Facts
Patent No.
US 7,241,571
App. No.
10/741,292
Granted
Jul 10, 2007
Kind
B2
Abstract

5-LO is expressed in the monocyte/macrophages (mono/mac) and foam cells of atherosclerotic lesions and is differentially expressed in CAST and CON6 mice relative to B6 mice. Mice heterozygous for a null mutation of 5-LO, when placed on an LDLR−/− background, have dramatically reduced atherosclerosis as compared to control LDLR −/− mice. In a genetic epidemiologic study, it is found that a common 5-LO polymorphism is strongly associated with carotid artery intima-media thickness (IMT) and coronary artery disease patients. These results indicate that 5-LO and the leukotriene biosynthetic pathway is a major contributor to atherogenesis in animal models, and in atherosclerosis susceptibility in humans.

Claims (8)

1. A method for detecting a predisposition to atherosclerosis in a human, the method comprising:

analyzing the genomic sequence of said human for the presence of predisposing 5-lipoxygenase (5-LO) alleles;

identifying, on both chromosomes, said alleles comprising not more than 4 SP1/Egr-1 binding sites instead of the common 5 tandemly repeated Sp1/Egr-1 binding sites in the 5-lipoxygenase promoter;

wherein the presence of said alleles is indicative that said human has a predisposition to atherosclerosis.

2. The method of claim 1 , wherein said analyzing the genomic sequence comprises the steps of:

amplifying a region of the 5-lipoxygenase promoter from isolated genomic DNA to provide an amplified fragment;

detecting the presence of a polymorphic sequence in said amplified fragment.

3. The method of claim 2 , wherein said detecting step comprises hybridization with a probe specific for the sequence of said polymorphism.

Assignments (4)
SECURITY INTEREST Recorded Oct 28, 2021
From: VET24SEVEN, INC.
To: FLOW CAPITAL CORP.
Reel/Frame 057949/0278 →
CONFIRMATORY LICENSE Recorded Jul 16, 2010
From: UNIVERSITY OF CALIFORNIA
To: NATIONAL INSTITUTES OF HEALTH (NIH), U.S. DEPT. OF HEALTH AND HUMAN SERVICES (DHHS), U.S. GOVERNMENT
Reel/Frame 024699/0297 →
CONFIRMATORY LICENSE Recorded Apr 16, 2008
From: UNIVERSITY OF CALIFORNIA
To: NATIONAL INSTITUTES OF HEALTH (NIH), U.S. DEPT. OF HEALTH AND HUMAN SERVICES (DHHS), U.S. GOVERNMENT
Reel/Frame 020812/0925 →
ASSIGNMENT OF ASSIGNOR'S INTEREST Recorded Jun 4, 2004
From: MEHRABIAN, MARGARET; LUSIS, ALDONS J.; ALLAYEE, HOOMAN
To: THE REGENTS OF THE UNIVERSITY OF CALIFORNIA
Reel/Frame 014696/0124 →
Continuity (3)
Continuation In Part PCTUS023420800 · Oct 24, 2002
Provisional Application 6033524400 · Oct 24, 2001
Related Publication 20040209288A1 · Oct 21, 2004